Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7753630 | 0.86 | NR1H4 (0.43) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL25584212 | 0.86 | KDM4E (0.55) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL29451106 | 0.80 | ALDH1A1 (0.57) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL696299 | 0.80 | ALDH1A1 (0.57) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL28246644 | 0.79 | GAA (0.46) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL7761954 | 0.78 | ALDH1A1 (0.55) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL9358883 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1MAPTCYP3A4GAA | |
| SCHEMBL29654078 | 0.78 | ALDH1A1 (0.57) | ALDH1A1MAPTESR2PTPN1TDP1 | |
| SCHEMBL1355541 | 0.78 | TDP1 (0.54) | KDM4EMAPTGAAPTPN1TDP1 | |
| SCHEMBL4631399 | 0.78 | TDP1 (0.59) | KDM4EALDH1A1TDP1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025100889-A1 | QUINAZOLINE DERIVATIVE, SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2025-05-15 | — | — | WO | disclosed |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| WO-2025046090-A1 | METHODS OF PREPARING PHOSPHONAMIDATE COMPOUNDS | TUBULIS GMBH (DE) | 2025-03-06 | — | — | WO | disclosed |
| EP-2956437-B1 | ALBICIDIN DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | UNIV BERLIN TECH (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-114206854-B | FXIa inhibitor and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| CN-114206854-A | FXIa inhibitor and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220040317-A1 | DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20210371379-A1 | NOVEL SALT OF 4-({(4S)-1-(4-CARBAMIMIDOYLBENZOYL)-4-[4(METHYLSULFONYL)PIPERAZIN-1-YL]-L-PROLYL}AMINO) BENZOIC ACID AND NOVEL CRYSTAL FORM THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3854783-A1 | NOVEL SALT OF 4-(\\{(4S)-1-(4-CARBAMIMIDOYLBENZOYL)-4-[4-(METHYLSULFONYL)PIPERAZIN-1-YL]-L-PROLYL\\}AMINO)BENZOIC ACID, AND AND NOVEL CRYSTAL FORM OF SAID SALT | ONO Pharmaceutical Co., Ltd. (JP) | 2021-07-28 | — | — | EP | disclosed |
| WO-1999043636-A2 | DISUBSTITUTED LAVENDUSTIN A ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE ANALOGS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THESECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5834468-A | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANALGESICS TREATING RHEUMATIC DISEASE, BONE DISORDER, INJURIES | ZENECA LIMITED (GB) | 1998-11-10 | — | — | US | disclosed |
| EP-0752421-A1 | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists | ZENECA LIMITED (GB) | 1997-01-08 | — | — | EP | disclosed |
| US-5395838-A | Aromatic aminomethyl substitutes compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-03-07 | — | — | US | disclosed |
| US-5110723-A | Assay for microorganisms; no surfactant necessary | EASTMAN KODAK COMPANY (US) | 1992-05-05 | — | — | US | disclosed |
| US-5089499-A | Anticarcinogenic agents; thymidylate synthetase inhibitors; antiallergens; psoriasis | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-18 | — | — | US | disclosed |
| US-5037762-A | Determination Of Enzymes, Metabolites Or Living Cells With Quinone Derivatives | EASTMAN KODAK COMPANY (US) | 1991-08-06 | — | — | US | disclosed |
| US-4983597-A | N-sulfonyl-2-azetidinone derivatives | MERCK & CO., INC. (US) | 1991-01-08 | — | — | US | disclosed |
| US-4853186-A | Water-compatible reducible compounds and their use in analytical compositions and methods | EASTMAN KODAK COMPANY (US) | 1989-08-01 | — | — | US | disclosed |
| US-4797357-A | FLUORESCENT DYES FOR MICROORGANISM DETECTION | EASTMAN KODAK COMPANY (US) | 1989-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371379-A1 | NOVEL SALT OF 4-({(4S)-1-(4-CARBAMIMIDOYLBENZOYL)-4-[4(METHYLSULFONYL)PIPERAZIN-1-YL]-L-PROLYL}AMINO) BENZOIC ACID AND NOVEL CRYSTAL FORM THEREOF | CLIC4, SBDS, SLC7A1 | KDM4E 35/4885ALDH1A1 1881/4885MAPT 627/4885 |
| US-12297207-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | SLC10A1, HNMT, OGFR | KDM4E 4593/4885ALDH1A1 317/4885MAPT 3597/4885 |
| US-20220040317-A1 | DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3 LIGASE LIGANDS AND METHODS OF USE | ALK, PTK2, CBL | KDM4E 1408/4885ALDH1A1 1843/4885MAPT 1807/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | KDM4E 4593/4885ALDH1A1 317/4885MAPT 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.